New Peripheral Pyridine-Substituted Cobalt, Copper, and Manganese Phthalocyanines as Potential In Vitro Acetyl/Butyrylcholinesterase Inhibitors in the Treatment of Alzheimer's Disease

YALAZAN H., SEYHAN G., Ozkan S., BARUT B., BIYIKLIOĞLU Z., KANTEKİN H.

APPLIED ORGANOMETALLIC CHEMISTRY, vol.39, no.3, 2025 (SCI-Expanded, Scopus) identifier identifier

  • Publication Type: Article / Article
  • Volume: 39 Issue: 3
  • Publication Date: 2025
  • Doi Number: 10.1002/aoc.70045
  • Journal Name: APPLIED ORGANOMETALLIC CHEMISTRY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Aerospace Database, BIOSIS, Chemical Abstracts Core, Chimica, Communication Abstracts, Compendex, Metadex, DIALNET, Civil Engineering Abstracts
  • Karadeniz Technical University Affiliated: Yes

Abstract

In this research, we designed phthalocyanine compounds that are thought to be used as potential acetyl/butyrylcholinesterase inhibitors in the treatment of Alzheimer's disease. First, phthalonitrile compound (PNM-CN), which is the precursor compound for phthalocyanines, was synthesized. Then, by cyclotetramerizing this compound, pyridine-substituted peripheral cobalt (PNM-CoPc), copper (PNM-CuPc), and manganese (PNM-MnClPc) phthalocyanine compounds were synthesized, and their structures were described using mass, NMR (except phthalocyanines), FT-IR, and UV-Vis (except phthalonitrile) spectroscopic techniques. Investigations were carried out into the new pyridine-substituted peripheral (PNM-Cu/Co/MnClPcs) phthalocyanines' in vitro inhibitory properties against butyrylcholinesterase (BuChE) and acetylcholinesterase (AChE). With an IC50 of 5.95 +/- 2.12 mu M (AChE) and 0.74 +/- 0.01 mu M (BuChE), PNM-CuPc showed the most potent inhibitory effect against AChE and BuChE among all compounds.